Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Pediatric pulmonology - 1 Oct 2015

Solomon George M, Marshall Susan G, Ramsey Bonnie W, Rowe Steven M

Abstract excerpt

Cystic Fibrosis is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene resulting in abnormal protein function. Recent advances of targeted molecular therapies and high throughput screening have resulted in multiple drug therapies that target many important mutations in the CFTR protein. In this review, we provide the latest results and current progress of CFTR modulators for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Aminophenols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aminopyridines

Share to Benzodioxoles

Share to Clinical Trials as Topic

Share to Drug Design

Share to Molecular Targeted Therapy

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 26097168
DOI: 10.1002/ppul.23240
PMCID: PMC4620567

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.PMID 26097168Read ↗

Cystic fibrosis transmembrane regulator correctors and potentiators.Semantic proximity Read ↗

Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.Semantic proximity Read ↗

Discovery of CFTR modulators for the treatment of cystic fibrosis.Semantic proximity Read ↗

Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Semantic proximity Read ↗

Toward inclusive therapy with CFTR modulators: Progress and challengesSemantic proximity Read ↗

Corrector combination therapies for F508del-CFTR.Semantic proximity Read ↗

CFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisSemantic proximity Read ↗

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Semantic proximity Read ↗

Current development of CFTR potentiators in the last decade.Semantic proximity Read ↗

New drugs in cystic fibrosis: what has changed in the last decade?Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.Semantic proximity Read ↗

Ion Channel Modulators in Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.